Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial ...

On its third-quarter earnings call Tuesday, Sage highlighted the launch of its Biogen-partnered postpartum depression drug ...

The partners no longer intend to develop Zurzuvae for one of the most common forms of depression, citing the time and cost of running new studies that would satisfy the FDA.

The drugmaker plans to prioritize the launch of its postpartum depression pill Zurzuvae, that has been jointly developed with ...

Sage Medical Manager and other software products from the Sage Healthcare Division. “This market is in such high-growth mode [and] we don’t have the internal resources to keep ...

Ten scientists are asking a California court to enforce a contractually obligated arbitration with Sage Publications after ...

Speaking on an earnings call in July, Laura Gault, chief medical officer at Sage, said SDMT has a similar design to the WAIS-IV coding test used in the Alzheimer’s study. The failed Parkinson ...